RAF1 and neoplasm: Furthermore, pan-RAF inhibitors in combination with MEKi led to increased anti-tumor TILs and potentiated the effects of anti-PD-L1 checkpoint inhibition in vivo, providing rationale for testing this combination in patients (Hong, Piva, et al., 2021).